Fetuin (AHSG, or Fetuin-A) has the highest capacity in inhibiting soft tissue calcification among all other molecules in the circulation. It is the most important and major calcification regulating protein in the circulation.
Fetuin, a glycoprotein present in the circulation, is synthesized by hepatocytes. The fetuin molecule consists of two polypeptide chains, which are both cleaved from a proprotein encoded from a single mRNA. The protein is commonly present in the cortical plate of the immature cerebral cortex and bone marrow hemopoietic matrix. However, its function of inhibiting soft tissue calcification is achieved by forming a soluble colloidal microsphere of fetuin-calcium-phosphate complex in the blood stream.
For patients with uremia on dialysis, a higher Ca x P product level accomplished with an abnormally lower fetuin level would have an extremely high risk of ectopic tissue / cardiovascular calcification. Even for those patients with an acceptable Ca x P product level, but an abnormal fetuin level the risk of calcification would be increased (please read the references below for more details)
- Risk assessment of ectopic tissue calcification in chronic renal failure
- Monitoring of soft tissue calcification in renal transplant recipients
- Diabetes related vascular calcification
- Risk stratification of acute coronary syndromes
- Arteriosclerosis related research
- Heart, aorta, valves calcifications